Augplat (Romiplostim) Injection

Description

Description

This page contains brief details about the drug romiplostim, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Romiplostim is a thrombopoietin receptor agonist which was approved for its medical use on 22nd August 2008.

Mechanism of Action of Romiplostim

Romiplostim Injection is medication belonging to the category of thrombopoietin receptor agonists. It activates human thrombopoietin receptors and induces the cells in the bone marrow to produce more platelets and arrests bleeding.

Uses of Romiplostim

Romiplostim Injection has been developed for adults and paediatric patients older than 1 year of age with immune thrombocytopenia, who have inadequately responded to corticosteroids, immunoglobulins and splenectomy.

Romiplostim Dosage available

A healthcare professional will administer Romiplostim injection to the patients through subcutaneous route. Romiplostim is available as single-dose lyophilized powder for injection in the doses 125mcg, 250mcg and 500mcg. The initial recommended dose is 1mcg/kg body weight once a week. The dose will be further adjusted according to the platelet response.